Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94527 trials found · Page 133 of 4727
-
Blood test guides combo therapy for hodgkin lymphoma relapse
Disease control Not yet recruitingThis is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investiga…
Phase: PHASE2 • Sponsor: Michael Spinner, MD • Aim: Disease control
Last updated May 15, 2026 10:13 UTC
-
New study tests glasses and eye drops to stop Kids' nearsightedness from worsening
Disease control Not yet recruitingTo date, randomized trials of low-concentration atropine eyedrops and specially designed spectacle lenses to slow the progression of myopia are limited in number and results are inconsistent in non-Asian children. Although results of some recent randomized clinical trials outsid…
Phase: PHASE3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated May 15, 2026 10:12 UTC
-
New combo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThe goal of this interventional study is to determine pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and Efti treatment. This is a prospective single arm interventional trial in patients with early-stage HR+/HER2 -ve breast cancer (Stage I-III) who are …
Phase: PHASE2 • Sponsor: George Washington University • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Magic mushroom therapy takes on alcoholism: new trial tests psilocybin doses
Disease control Not yet recruitingThis study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will u…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
New combo therapy aims to tame leukemia without lifelong pills
Disease control Not yet recruitingThe goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Engineered immune cells take on hard-to-treat cancers in early trial
Disease control Not yet recruitingOnly enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New hope for brain metastases: drug combo targets tumors in the brain
Disease control Not yet recruitingBrain metastasis represents one of the worst prognostic outcomes in advanced malignant tumors. Approximately 10% to 40% of patients with solid tumors develop brain metastases, a incidence rate significantly higher than that of primary malignant brain tumors. Over 80% of patients …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New hope for advanced penile cancer: drug combo targets tough cases
Disease control Not yet recruitingPenile cancer is a rare malignant tumor of the male genitourinary system, with 95% being squamous cell carcinoma. Due to social factors, delayed diagnosis is common, leading to a high rate of lymph node metastasis (17%-45% at diagnosis), which significantly impairs quality of lif…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Targeted drug and radiation team up to fight aggressive kidney cancer
Disease control Not yet recruitingThis randomized, open-label, multicenter phase II study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial carcinoma after radical nephroureterectomy (RNU). Eli…
Phase: PHASE2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Promising new combo therapy targets deadly childhood brain tumor
Disease control Not yet recruitingThis is a multi-treatment arm study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC).The study will assess the safety and efficacy of novel therapies and combinatorial strategies for participants with recurrent or progressive ATRT.
Phase: PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Promising drug cocktail aims to boost esophageal cancer surgery success
Disease control Not yet recruitingIn the management of locally advanced esophageal squamous cell carcinoma, the outcomes associated with surgical resection, whether conducted alone or supplemented with postoperative adjuvant radiotherapy and chemotherapy, have been suboptimal. Immune checkpoint inhibitors (ICIs) …
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Triple-drug attack aims to shrink tough skin cancers before surgery
Disease control Not yet recruitingThis is a single-arm, open-label, single-center, Phase II exploratory clinical study evaluating the efficacy, safety, and tolerability of neoadjuvant pucotenlimab combined with lenvatinib and temozolomide in patients with resectable Stage IIB/III acral melanoma. After providing …
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
New triple therapy targets rare neuroendocrine cancers in first-line trial
Disease control Not yet recruitingTo explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinoma (EP-NEC)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 15, 2026 10:14 UTC
-
New combo therapy aims to boost depression treatment success
Symptom relief Recruiting nowRepetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated May 01, 2026 15:57 UTC
-
New urine test could spare men unnecessary prostate biopsies
Diagnosis Not yet recruitingThis clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likeliho…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Diagnosis
Last updated May 07, 2026 18:41 UTC
-
Gene therapy hope for rare AGU disease enters human trials
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the treatment is a safe, tolerable, and efficacious treatment for adults and children with Aspartylglucosaminuria (AGU).
Phase: PHASE1, PHASE2 • Sponsor: Rare Trait Hope • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Nasal spray may ward off Post-Surgery confusion in seniors
Symptom relief Not yet recruitingThis study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.
Phase: PHASE2, PHASE3 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Symptom relief
Last updated May 15, 2026 10:10 UTC
-
Second chance: new stroke treatment could save more brain tissue
Disease control Not yet recruitingIschemic cerebrovascular disease is a common neurological disorder with high incidence, mortality, and disability. Early reperfusion to salvage the ischemic penumbra is the cornerstone of acute ischemic stroke (AIS) treatment. Current reperfusion strategies include intravenous th…
Phase: PHASE2 • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Bone-Stretching trick may save feet from diabetes wounds
Disease control Not yet recruitingThis study is a single-center, prospective, randomized controlled trial aimed at evaluating whether periosteal distraction combined with autologous split-thickness skin grafting can significantly improve graft survival rate at postoperative day 14 compared with skin grafting alon…
Phase: NA • Sponsor: Hu Zhicheng • Aim: Disease control
Last updated May 15, 2026 10:12 UTC
-
Shorter radiation plus immunotherapy may improve rectal cancer outcomes
Disease control Not yet recruitingIn this prospective, multicentre, randomized phase III trial, 612 locally advanced rectal cancer (LARC, T3-4/N+M0) patients with at least one high-risk features (lower location (≤5cm), cT4, cN2, MRF+, EMVI+, TD+) will be included, and randomly assigned to TNT group and iTNT group…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 11, 2026 20:50 UTC